Urine Proteome in Distinguishing Hepatic Steatosis in Patients with Metabolic-Associated Fatty Liver Disease

Urine Proteome in Distinguishing Hepatic Steatosis in Patients with Metabolic-Associated Fatty Liver Disease

Background: In patients with metabolic-associated fatty liver disease (MAFLD), hepatic steatosis is the first step of diagnosis, and it is a risk predictor that independently predicts insulin resistance, cardiovascular risk, and mortality. Urine biomarkers have the advantage of being less complex, w...

Full description

Bibliographic Details
Main Authors: Chang-Hai Liu, Shanshan Zheng, Shisheng Wang, Dongbo Wu, Wei Jiang, Qingmin Zeng, Yi Wei, Yong Zhang, Hong Tang
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Diagnostics
Subjects:
metabolic-associated fatty liver disease
proteomics
hepatic steatosis
Online Access:https://www.mdpi.com/2075-4418/12/6/1412

Internet

https://www.mdpi.com/2075-4418/12/6/1412

Similar Items